Please upgrade your browser.
In a study of 256 patients treated surgically for renal cell carcinoma (RCC) with venous thrombus at the University of Texas MD Anderson Cancer Center between 1993 and 2009, median recurrence-free interval was significantly shorter in patients with positive vascular margins (22.1 months vs 70.2 months). However, although tumour invasion into the vein wall at the resection margin was independently predictive of local recurrence, multivariable analysis revealed that it had minimal effect on systemic recurrence or cancer-specific survival.
Whitehead Institute scientists report that the gene mutated in the rare hereditary disorder known as Birt-Hogg-Dubé cancer syndrome also prevents activation of mTORC1, a critical nutrient-sensing and growth-regulating cellular pathway.
A panel of experts differs in opinion on the treatment of various kidney cancers. Recorded at M. D. Anderson Cancer Center, Houston, Texas, in 2013.
Standard treatment of renal neoplasms remains surgical resection, and nephrectomy for localised renal cell carcinoma (RCC) still has the best chance of cure with excellent long-term results. For smaller renal masses, especially stage T1a tumours less than 4 cm, nephron-sparing surgery is often employed. However, small incidentally detected renal masses pose an important diagnostic dilemma...
Tumour shrinkage measured with first treatment evaluation under VEGF-targeted therapy as prognostic marker
Tumour shrinkage measured with first treatment evaluation under VEGF-targeted therapy as prognostic marker in metastatic renal cell carcinoma (mRCC).
Very few studies have followed patients with renal cell carcinoma for long enough to characterize late relapses. Newly published research suggests that late-recurring tumours are more likely to be of low nuclear grade and show a better response...
Evidence from a Meta-Analysis of Observational Studies
Christopher G. Wood, M.D., F.A.C.S., was honored at the 12th International Kidney Cancer Symposium, held in Chicago, for his career-long commitment to advancing kidney cancer research.
In two independent analyses comparing robotic-assisted surgery and open surgery performed on patients with urologic cancers, researchers found that robotic-assisted surgery results in fewer overall complications during and after surgery, less blood loss and shorter length of hospital stay.
Designed to Target Advanced Metastatic Renal Cell Carcinoma, the Study Will Determine the Maximum Tolerated Dose of Debio 0932 in Combination With Everolimus.
|Powered by NeonCRM|